Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K

Phototherapy in Scleroderma.

John Hassani1, Steven R Feldman2

  • 1Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. jhassani@nyit.edu.

Dermatology and Therapy
|August 13, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Indurated Mass on the Right Central Back.

Cutis·2022
Same author

The role of nitric oxide in melanoma.

Biochimica et biophysica acta. Reviews on cancer·2017
Same author

Intraperitoneal Rosai-Dorfman disease associated with clear cell sarcoma: first case report.

Pathology·2016
Same author

Blood vessel occlusion in peri-burn tissue is secondary to erythrocyte aggregation and mitigated by a fibronectin-derived peptide that limits burn injury progression.

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society·2016
Same author

Tanning Bed Perception Survey: A Questionnaire-based Study.

The Journal of clinical and aesthetic dermatology·2015
Same author

Osteopathic manipulative treatment as a useful adjunctive tool for pneumonia.

Journal of visualized experiments : JoVE·2014
Same journal

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival.

Dermatology and therapy·2026
Same journal

Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.

Dermatology and therapy·2026
Same journal

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.

Dermatology and therapy·2026
Same journal

Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials.

Dermatology and therapy·2026
Same journal

The Impact of Chronic Spontaneous Urticaria on Sleep-A Systematic Review.

Dermatology and therapy·2026
Same journal

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy.

Dermatology and therapy·2026
See all related articles

Phototherapy shows promise for treating systemic and localized scleroderma, though more research is needed. Ultraviolet A1 (UVA1) therapy, 3-4 times weekly for 30 treatments, is suggested based on current evidence.

Area of Science:

  • Dermatology
  • Photomedicine

Background:

  • Scleroderma, including systemic and localized forms, presents significant management challenges with no established gold standard therapy.
  • Phototherapy is emerging as a promising treatment modality for scleroderma.

Approach:

  • A comprehensive PubMed search was conducted to gather information on phototherapy for scleroderma.
  • Studies were categorized based on their evaluation of effects on disease pathogenesis and clinical outcomes.
  • Photopheresis studies were excluded from the analysis.

Key Points:

  • The majority of identified studies focused on ultraviolet A1 (UVA1) phototherapy.
  • A significant limitation is the lack of randomized, double-blind, placebo-controlled studies, with only three controlled studies identified.
  • Limited evidence suggests a treatment protocol of 20-50 J/cm² of UVA1, administered 3-4 times per week for a total of 30 treatments.
Keywords:
MorpheaPUVAPhototherapySclerodermaUVAUVB

More Related Videos

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.1K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.4K

Related Experiment Videos

Last Updated: Mar 16, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.6K
Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.1K
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

9.4K

Conclusions:

  • Current evidence for phototherapy in scleroderma treatment is based on limited, often uncontrolled, studies.
  • More rigorous research, including randomized controlled trials, is essential to establish definitive treatment guidelines for phototherapy in scleroderma.
  • The recommended UVA1 regimen requires further validation through high-quality clinical trials.